Society for Clinical Trials

Contents

Society for Clinical Trials is a professional association dedicated to advancing the design, conduct, analysis, and reporting of randomized clinical trials. Founded in 1978, the organization brings together biostatisticians, epidemiologists, clinicians, regulators, and methodologists from institutions such as Johns Hopkins University, National Institutes of Health, Food and Drug Administration, World Health Organization, and Centers for Disease Control and Prevention. Its activities intersect with major trials and trials infrastructure linked to ClinicalTrials.gov, CONSORT, ICH Good Clinical Practice, Cochrane Collaboration, and academic centers like Harvard University, University of Oxford, and University of California, San Francisco.

History

The Society emerged amid methodological debates in the 1970s involving figures and institutions such as Frederick Mosteller, John Tukey, National Heart, Lung, and Blood Institute, Medical Research Council, National Cancer Institute, and events like the Tuskegee syphilis study aftermath and reforms responding to the Helsinki Declaration. Early meetings attracted leaders from World Bank-funded public health trials, pioneers from MRC Clinical Trials Unit, and statisticians associated with Bernard Lown, Richard Peto, Peter Armitage, and Sir Austin Bradford Hill. The Society’s formation paralleled the rise of trial registries such as ClinicalTrials.gov and reporting standards later codified in CONSORT and regulatory harmonization under ICH. Over decades SCT has engaged with policy debates involving Food and Drug Administration Modernization Act deliberations, large-scale trials sponsored by National Institutes of Health, and global initiatives coordinated by World Health Organization and Pan American Health Organization.

The Society’s mission emphasizes methodological rigor and ethical conduct, aligning with organizations like Cochrane Collaboration, CONSORT Group, International Epidemiological Association, International Society for Clinical Biostatistics, and Global health consortia. Activities include organizing symposia paralleling conferences at American Statistical Association, Royal Statistical Society, International Biometric Society, and collaborating with regulatory agencies such as the Food and Drug Administration, European Medicines Agency, and Health Canada. The Society runs educational workshops that feature methodologies developed by researchers affiliated with Harvard School of Public Health, Columbia University, Stanford University, Yale School of Medicine, and statistical groups at London School of Hygiene & Tropical Medicine.

Membership spans professionals from academic departments including Johns Hopkins Bloomberg School of Public Health, University of Washington, University of Minnesota, clinical trial units like MRC Clinical Trials Unit and Fred Hutchinson Cancer Research Center, and regulatory bodies such as the National Institutes of Health and Food and Drug Administration. Governance structures reflect models used by American Statistical Association and Royal Statistical Society with elected officers, an executive committee, and standing committees for ethics, education, and awards. Presidents and board members have come from institutions such as Harvard University, University College London, University of Toronto, Mayo Clinic, and University of Oxford.

The Society disseminates methodological advances through newsletters, proceedings, and collaborations with journals such as The Lancet, New England Journal of Medicine, Journal of the American Medical Association, British Medical Journal, and specialty outlets like Statistics in Medicine and Clinical Trials. It promotes frameworks related to CONSORT reporting, engages with editorial standards at PLOS Medicine, Annals of Internal Medicine, Nature Medicine, and supports guidance from International Committee of Medical Journal Editors. Communications channels mirror practices from American Journal of Epidemiology and Biometrika, and the Society contributes to white papers used by WHO and European Medicines Agency.

The Society has shaped randomized trial methodology through dialogues involving leaders from MRC, NIH, FDA, EMA, and academic trailblazers such as Donald Rubin, Bradley Efron, Nan Laird, Jerome Cornfield, Richard Peto, and Peter Armitage. Contributions include promotion of randomization methods, interim analysis procedures related to work by James O. Berger and Daniel Schwarz, adaptive designs informed by researchers at Carnegie Mellon University and University of Pennsylvania, and causal inference frameworks linked to Judea Pearl and Donald Rubin. The Society’s influence extends to large-scale pragmatic trials coordinated with networks like PCORI, NIHR, DFID, and initiatives tied to Global Fund projects, affecting practice in cardiology trials influenced by Framingham Heart Study, oncology trials guided by NCI, and vaccine trials associated with Bill & Melinda Gates Foundation funding.

Category:Clinical trials organizations